tiprankstipranks
Innovent Biologics (HK:1801)
:1801
Hong Kong Market
1801
Innovent Biologics
RESEARCH TOOLSreports
Want to see HK:1801 full AI Analyst Report?

Innovent Biologics (1801) Stock Forecast & Price Target

28 Followers
See the Price Targets and Ratings of:

1801 Analyst Ratings

Strong Buy
18Ratings
Strong Buy
18 Buy
0 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Innovent
Biologics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1801 Stock 12 Month Forecast

Average Price Target

HK$132.01
▲(31.88% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is HK$132.01 with a high forecast of HK$150.23 and a low forecast of HK$112.00. The average price target represents a 31.88% change from the last price of HK$100.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"HK$75","94":"HK$94","113":"HK$113","132":"HK$132","151":"HK$151"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$150.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":132.01333333333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$132.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,94,113,132,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.7,91.58692307692309,96.47384615384615,101.36076923076924,106.2476923076923,111.13461538461539,116.02153846153846,120.90846153846154,125.79538461538462,130.6823076923077,135.56923076923076,140.45615384615382,145.34307692307692,{"y":150.23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.7,90.18564102564103,93.67128205128205,97.15692307692308,100.64256410256411,104.12820512820512,107.61384615384615,111.09948717948717,114.5851282051282,118.07076923076923,121.55641025641025,125.04205128205128,128.5276923076923,{"y":132.01333333333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.7,88.64615384615385,90.5923076923077,92.53846153846155,94.48461538461538,96.43076923076923,98.37692307692308,100.32307692307693,102.26923076923077,104.21538461538461,106.16153846153847,108.1076923076923,110.05384615384615,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.7,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$150.23Average Price TargetHK$132.01Lowest Price TargetHK$112.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on HK:1801
Unknown Analyst
Citi
Not Ranked
Citi
HK$115→HK$149.6
Buy
49.45%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from Citi
Jefferies Analyst forecast on HK:1801
Unknown Analyst
Jefferies
Not Ranked
Jefferies
HK$125
Buy
24.88%
Upside
Reiterated
08/27/26
Jefferies Remains a Buy on Innovent Biologics (IVBXF)
J.P. Morgan Analyst forecast on HK:1801
Yang Huang
J.P. Morgan
J.P. Morgan
HK$117→HK$140
Buy
39.86%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from J.P. Morgan
CMB International Securities Analyst forecast on HK:1801
Jill Wu
CMB International Securities
CMB International Securities
HK$130.25
Buy
30.12%
Upside
Reiterated
08/27/26
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
CLSA Analyst forecast on HK:1801
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$139.9→HK$146.1
Buy
45.95%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Receives a Buy from CLSA
Daiwa Analyst forecast on HK:1801
Unknown Analyst
Daiwa
Not Ranked
Daiwa
HK$120→HK$135
Buy
34.87%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Gets a Buy from Daiwa
CICC Analyst forecast on HK:1801
Unknown Analyst
CICC
Not Ranked
CICC
HK$118.3
Buy
18.18%
Upside
Reiterated
08/26/26
CICC Remains a Buy on Innovent Biologics (IVBXF)
DBS Analyst forecast on HK:1801
Mark Kong CFA
DBS
DBS
HK$144
Buy
43.86%
Upside
Reiterated
08/26/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (Other OTC: NNCSF) and Innovent Biologics (Other OTC: IVBXF)
Morgan Stanley Analyst forecast on HK:1801
Jack Lin
Morgan Stanley
Morgan Stanley
HK$138.5
Buy
38.36%
Upside
Reiterated
08/25/26
Jack Lin Reiterates Buy on Innovent Biologics, Citing Strong Profitability, Solid Revenue Growth, and De-Risked Late-Stage Pipeline
Guotai Haitong Analyst forecast on HK:1801
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$119.79
Buy
19.67%
Upside
Reiterated
08/25/26
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
Sinolink Securities Analyst forecast on HK:1801
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$150.23
Buy
50.08%
Upside
Reiterated
08/25/26
Sinolink Securities Sticks to Its Buy Rating for Innovent Biologics (IVBXF)
BOCOM International Holdings Company Analyst forecast on HK:1801
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$105→HK$118
Buy
17.88%
Upside
Reiterated
08/06/26
BOCOM International Holdings Company Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
UOB Kay Hian Analyst forecast on HK:1801
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$112
Buy
11.89%
Upside
Reiterated
07/15/26
UOB Kay Hian Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
UBS Analyst forecast on HK:1801
Unknown Analyst
UBS
Not Ranked
UBS
HK$124→HK$124.1
Buy
23.98%
Upside
Reiterated
07/14/26
UBS Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
HSBC Analyst forecast on HK:1801
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$120
Buy
19.88%
Upside
Reiterated
07/10/26
HSBC Remains a Buy on Innovent Biologics (IVBXF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on HK:1801
Unknown Analyst
Citi
Not Ranked
Citi
HK$115→HK$149.6
Buy
49.45%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from Citi
Jefferies Analyst forecast on HK:1801
Unknown Analyst
Jefferies
Not Ranked
Jefferies
HK$125
Buy
24.88%
Upside
Reiterated
08/27/26
Jefferies Remains a Buy on Innovent Biologics (IVBXF)
J.P. Morgan Analyst forecast on HK:1801
Yang Huang
J.P. Morgan
J.P. Morgan
HK$117→HK$140
Buy
39.86%
Upside
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from J.P. Morgan
CMB International Securities Analyst forecast on HK:1801
Jill Wu
CMB International Securities
CMB International Securities
HK$130.25
Buy
30.12%
Upside
Reiterated
08/27/26
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
CLSA Analyst forecast on HK:1801
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$139.9→HK$146.1
Buy
45.95%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Receives a Buy from CLSA
Daiwa Analyst forecast on HK:1801
Unknown Analyst
Daiwa
Not Ranked
Daiwa
HK$120→HK$135
Buy
34.87%
Upside
Reiterated
08/26/26
Innovent Biologics (IVBXF) Gets a Buy from Daiwa
CICC Analyst forecast on HK:1801
Unknown Analyst
CICC
Not Ranked
CICC
HK$118.3
Buy
18.18%
Upside
Reiterated
08/26/26
CICC Remains a Buy on Innovent Biologics (IVBXF)
DBS Analyst forecast on HK:1801
Mark Kong CFA
DBS
DBS
HK$144
Buy
43.86%
Upside
Reiterated
08/26/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (Other OTC: NNCSF) and Innovent Biologics (Other OTC: IVBXF)
Morgan Stanley Analyst forecast on HK:1801
Jack Lin
Morgan Stanley
Morgan Stanley
HK$138.5
Buy
38.36%
Upside
Reiterated
08/25/26
Jack Lin Reiterates Buy on Innovent Biologics, Citing Strong Profitability, Solid Revenue Growth, and De-Risked Late-Stage Pipeline
Guotai Haitong Analyst forecast on HK:1801
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$119.79
Buy
19.67%
Upside
Reiterated
08/25/26
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
Sinolink Securities Analyst forecast on HK:1801
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$150.23
Buy
50.08%
Upside
Reiterated
08/25/26
Sinolink Securities Sticks to Its Buy Rating for Innovent Biologics (IVBXF)
BOCOM International Holdings Company Analyst forecast on HK:1801
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$105→HK$118
Buy
17.88%
Upside
Reiterated
08/06/26
BOCOM International Holdings Company Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
UOB Kay Hian Analyst forecast on HK:1801
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$112
Buy
11.89%
Upside
Reiterated
07/15/26
UOB Kay Hian Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
UBS Analyst forecast on HK:1801
Unknown Analyst
UBS
Not Ranked
UBS
HK$124→HK$124.1
Buy
23.98%
Upside
Reiterated
07/14/26
UBS Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
HSBC Analyst forecast on HK:1801
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$120
Buy
19.88%
Upside
Reiterated
07/10/26
HSBC Remains a Buy on Innovent Biologics (IVBXF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

3 Months
Jill WuCMB International Securities
Success Rate
8/13 ratings generated profit
62%
Average Return
+13.35%
Copying Jill Wu's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +13.35% per trade.
1 Year
Rebecca LiangBernstein
Success Rate
11/12 ratings generated profit
92%
Average Return
+41.53%
Copying Rebecca Liang's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +41.53% per trade.
2 Years
Jill WuCMB International Securities
Success Rate
13/13 ratings generated profit
100%
Average Return
+105.59%
Copying Jill Wu's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +105.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1801 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
9
10
11
6
Buy
15
12
8
8
22
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
21
18
19
28
In the current month, 1801 has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1801 average Analyst price target in the past 3 months is 132.01.
Each month's total comprises the sum of three months' worth of ratings.

1801 Financial Forecast

1801 Earnings Forecast

Next quarter’s earnings estimate for 1801 is HK$1.33 with a range of HK$1.33 to HK$1.33. The previous quarter’s EPS was HK$0.82. 1801 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1801 is HK$1.33 with a range of HK$1.33 to HK$1.33. The previous quarter’s EPS was HK$0.82. 1801 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.

1801 Sales Forecast

Next quarter’s sales forecast for 1801 is HK$11.85B with a range of HK$10.78B to HK$12.93B. The previous quarter’s sales results were HK$9.82B. 1801 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.
Next quarter’s sales forecast for 1801 is HK$11.85B with a range of HK$10.78B to HK$12.93B. The previous quarter’s sales results were HK$9.82B. 1801 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.

1801 Stock Forecast FAQ

What is HK:1801’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is 132.01.
    What is HK:1801’s upside potential, based on the analysts’ average price target?
    Innovent Biologics has 31.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Innovent Biologics a Buy, Sell or Hold?
          Innovent Biologics has a consensus rating of Strong Buy, which is based on 18 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Innovent Biologics’s share price target?
            The average share price target for Innovent Biologics is 132.01. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$150.23 ,and the lowest forecast is HK$112.00. The average share price target represents 31.88% Increase from the current price of HK$100.1.
              What do analysts say about Innovent Biologics?
              Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of Innovent Biologics?
                To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.